7 citations
,
April 2021 in “Journal of advanced pharmaceutical technology & research” This study reported that compound 16 (olean-12-en-3beta-ol, cinnamate) from Merremia peltata showed potential as an androgen receptor antagonist, suggesting it may benefit alopecia treatment based on molecular docking and ADME-Tox predictions.
March 2026 in “Jurnal Pharmascience” This study found that isorhamnetin, a compound from the Rampai plant, showed a lower affinity energy in molecular docking tests compared to Minoxidil, indicating potential as an androgen receptor antagonist for alopecia therapy in silico, with favorable pharmacokinetic characteristics in ADME-Tox predictions.
May 2024 in “EAS Journal of Pharmacy and Pharmacology” In this study, researchers used molecular docking to show that compounds from pomegranate peels, such as apigenin, luteolin, and taxifolin, effectively inhibit the enzyme 5α-reductase, suggesting potential anti-alopecic properties.
4 citations
,
August 2022 in “The Scientific World Journal” This study found that bufotalinin, derived from Merremia peltata leaves, may enhance hair growth by acting as a potential androgen receptor antagonist in rabbits.
3 citations
,
March 2022 in “Research journal of pharmacy and technology” This study found that the compound (+)–Marmesin from Petroselinum crispum showed potential as an anti-alopecia agent by demonstrating better binding to androgen receptors than minoxidil, though not surpassing native ligands.